Compare · DXCM vs KMTS
DXCM vs KMTS
Side-by-side comparison of DexCom Inc. (DXCM) and Kestra Medical Technologies Ltd. (KMTS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and KMTS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $28.08B, about 25.6x KMTS ($1.10B).
- DXCM has been more active in the news (30 items in the past 4 weeks vs 1 for KMTS).
- DXCM has more recent analyst coverage (25 ratings vs 7 for KMTS).
- Company
- DexCom Inc.
- Kestra Medical Technologies Ltd.
- Price
- -
- -
- Market cap
- $28.08B
- $1.10B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2025
- News (4w)
- 30
- 1
- Recent ratings
- 25
- 7
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest DXCM
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
- Director Driscoll Rimma was granted 5,605 shares, increasing direct ownership by 48% to 17,319 units (SEC Form 4)
- Director Ashley Euan A. was granted 5,565 shares, increasing direct ownership by 78% to 12,731 units (SEC Form 4)
- Director Collins Richard Alexander was granted 5,605 shares (SEC Form 4)
Latest KMTS
- Officer Webster Brian Daniel sold $314,329 worth of shares (15,000 units at $20.96) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 334,786 units (SEC Form 4)
- Kestra Medical Technologies to Present at the BofA Securities 2026 Healthcare Conference
- Kestra Showcases Accelerated Innovation at HRS 2026
- SEC Form 4 filed by Webster Brian Daniel
- Kestra Medical Technologies Named a 2026 USA TODAY Top Workplaces Award Winner
- Amendment: SEC Form SCHEDULE 13G/A filed by Kestra Medical Technologies Ltd.
- SEC Form S-3ASR filed by Kestra Medical Technologies Ltd.
- SEC Form 4 filed by Cohen Raymond W
- Kestra Medical Technologies Named Finalist for 2026 GeekWire "Deal of the Year"
- SEC Form 4 filed by Webster Brian Daniel